Method for treating bladder cancer through promoting pharmorubicin by bacillus calmette guerin vaccine

A technology for epirubicin and bladder cancer, applied in the field of BCG to promote epirubicin in the treatment of bladder cancer, can solve the problems of no combined perfusion, single, different tumor action mechanisms, etc.

Pending Publication Date: 2019-04-26
GUANGDONG PHARMA UNIV
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The above-mentioned drug infusions have different mechanisms of action on tumors, and they all use a single drug infusion. Whether combined application has a better effect has not yet been

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating bladder cancer through promoting pharmorubicin by bacillus calmette guerin vaccine
  • Method for treating bladder cancer through promoting pharmorubicin by bacillus calmette guerin vaccine
  • Method for treating bladder cancer through promoting pharmorubicin by bacillus calmette guerin vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] The invention provides a method for BCG to promote epirubicin to treat bladder cancer, including a method for studying the synergistic effect of BCG on epirubicin at the cell level and a method for the synergistic effect of BCG on epirubicin in vivo;

[0055] The invention provides a method for studying the synergistic effect of BCG on epirubicin at the cellular level, and the specific steps are as follows:

[0056] Step 1. Cell culture: at 37°C, 5% CO 2 MEM medium containing 10% fetal bovine serum is used for culture under the condition, and the medium is changed or passaged every 2-3 days;

[0057] Step 2. Cell viability detection: Use the CCK8 cell viability detection kit to collect logarithmic phase human bladder cancer UMUC3 cells, adjust the cell concentration to 5×104 / mL, inoculate 100 μL per well in a 96-well plate, and place in an incubator overnight ;

[0058] Step 3. After the cells adhere to the wall, add the corresponding drugs according to different conc...

Embodiment 2

[0103] In Example 1, CCK8 was used to detect cell activity, and calculated according to the OD value to detect the effect of drugs on cell activity. The specific experiments are as follows:

[0104]

[0105] Epirubicin alone acted on human bladder cancer UMUC3 cells at different concentrations for 48 and 72 hours. With the increase of concentration and the prolongation of time, the activity of human bladder cancer UMUC3 cells decreased; 0.1473μM;

[0106]

[0107] BCG alone acts on human bladder cancer UMUC3 cells at different concentrations for 24 and 48 hours. With the increase of concentration and the prolongation of time, the activity of human bladder cancer UMUC3 cells decreases;

[0108]

[0109] Epirubicin (0.3μM) combined with different concentrations of BCG acted on human bladder cancer cells for 24 and 48 hours. With the increase of BCG concentration and the prolongation of time, the activity of human bladder cancer UMUC3 cells decreased;

[0110]

[011...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for treating bladder cancer through promoting pharmorubicin by a bacillus calmette guerin vaccine (BCG), and specifically relates to the field of combined treatment ofthe bladder cancer in clinical medicine. The method comprises a method for researching synergism of the BCG to the pharmorubicin in a cellular level and a method for synergism of the in-vivo BCG to the pharmorubicin. According to the invention, through using the method for researching the synergism of the BCG to the pharmorubicin in the cellular level and the method for the synergism of the in-vivo BCG to the pharmorubicin, a combined medication scheme is provided to improve treatment efficiency and reduce toxic and side effects during drug perfusion. The method disclosed by the invention isnot high in prefused drug concentration, but long in intra-bladder retention time, thereby being better in the anti-tumor effect without generating an adverse reaction.

Description

technical field [0001] The invention relates to the technical field of combination therapy against bladder cancer in clinical medicine, more specifically, the invention relates to a method for BCG-promoting epirubicin to treat bladder cancer. Background technique [0002] Bladder cancer is the most common malignant tumor of the urinary system in my country, with more than 50,000 new cases every year. More than 90% of them are derived from transitional epithelial cells of the bladder mucosa, 5-10% are squamous cell carcinomas, and 2-3% are adenocarcinomas. The treatment method mostly adopts transurethral resection (TUR) to completely remove the visible tumor, and supplemented with adjuvant perfusion therapy to prevent the recurrence and progression of the tumor. According to statistics, among bladder cancer patients, 75-85% of bladder cancers are superficial cancers, 50-80% of superficial cancers will recur one year after surgery, and 10-30% of recurrent tumors will increase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/04A61K31/704A61P13/10A61P35/00C12Q1/02
CPCA61K39/04A61P13/10A61P35/00G01N33/5011A61K9/0034A61K31/704G01N2500/10C12N2503/02
Inventor 孟民杰董斌田素娟骆阳傅晓仪
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap